Department of Cardiac Surgery, Dr Antoni Jurasz Memorial University Hospital
Bydgoszcz, Kuyavian-Pomeranian Voivodeship, 85-001, Poland
NCT Number: NCT03074604
The objective of this study is to investigate the value of employing the aortic no-touch off-pump coronary artery bypass technique and the practice of carbon dioxide surgical field flooding for the prevention of type 1 and 2 neurological injuries following surgical coronary revascularization.
Looking for future studies?
Notify Me60 year and older
All sexes
Interventional
Not applicable
Bydgoszcz, Kuyavian-Pomeranian Voivodeship, 85-001, Poland
Neurological injuries remain a major concern following coronary artery bypass grafting (CABG) that offset survival benefit of CABG over percutaneous coronary interventions. Among numerous efforts to combat this issue, is off-pump CABG (OPCABG) that obviates the need for extracorporeal circulation and is associated with improved outcomes. The objective of this study is to examine whether the neuroprotective effect of OPCABG can be further pronounced by the use of two state-of-the-art operating techniques.
In this randomised, controlled, investigator and patient blinded single center superiority trial with three parallel arms a total of 360 patients will be recruited. They will be allocated in a 1:1:1 ratio to two treatment and one control arms. Treatment arms undergoing either aortic no-touch OPCABG or OPCABG with a partial clamp applying carbon dioxide surgical field flooding will be compared against control arm undergoing OPCABG. The primary endpoint will be the appearance of new lesions on control brain magnetic resonance imaging 3 days after surgery. Secondary endpoints will include the prevalence of new focal neurological deficits in the first 7 days after surgery, the occurrence of postoperative cognitive dysfunction at either 1 week or 3 months after surgery and the incidence of delirium in the first 7 days after surgery. Data will be analysed on intention-to-treat principles and a per protocol basis.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
(Study arm 1) In this intervention only the internal mammary artery grafts will be used (i.e. left internal mammary artery graft, right internal mammary artery graft, or a Y-graft that uses right internal mammary artery graft anastomosed onto left internal mammary artery graft to allow for a wide territory of myocardial revascularization). However, in the rare event that the aforementioned approach is insufficient to reach all target vessels, a reversed (great) saphenous vein graft may be used to extend the left internal mammary artery graft or the right internal mammary artery graft.
(Study arm 2) In this intervention chest cavity will be insufflated with carbon dioxide at a flow above 5 l/min during the entire surgical procedure.
(Study arm 3) This is the control arm undergoing "traditional" OPCABG with partial clamp.
Time frame: 3 days after surgery
Appearance of new lesions on control brain magnetic resonance imaging 3 days after surgery.
Time frame: 7 days after surgery
Prevalence of new focal neurological deficits in the first 7 days after surgery.
Time frame: 1 week or 3 months after surgery
Occurrence of postoperative cognitive dysfunction at either 1 week or 3 months after surgery
Time frame: 7 days after surgery
Incidence of delirium in the first 7 days after surgery.
Collegium Medicum w Bydgoszczy
Other
Acronym: CANON
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04607330
Brain Diseases, Cancer
Worthing, West Sussex, United Kingdom
View Trial DetailsNCT04755699
Brain Diseases, Cardiovascular Diseases
Manhasset, New York, United States
View Trial DetailsNCT05536921
Brain Damage, Chronic, Brain Diseases
Częstochowa, Poland
View Trial DetailsNCT04286191
Central Nervous System Diseases, Muscle Hypertonia
Charleston, South Carolina, United States
View Trial Details